Olatoyosi M Odenike MD

PubMed

• Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.
  Fieke W Hoff, Joshua F Zeidner, Geeta Torlapati, Deedra Nicolet, Krzysztof Mrózek
  American Journal of Hematology. 2026-09-01
• Targeting Menin in T-lineage Acute Lymphoblastic Leukemia.
  Kathryn Shimamoto, Diren Arda Karaoglu, Olivia Arnold, Arjun Dhar, Zachary Chan
  Molecular Cancer Therapeutics. 2026-08-04
• OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML.
  Uma M Borate, Ying Huang, Tara L Lin, Shivani Handa, Ronan Swords
  Blood. 2026-07-28

Journal Articles

• How I Treat Blast Phase of Philadelphia-Negative Myeloproliferative Neoplasms  
  Olatoyosi Odenike, MD, Blood
• T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia  
  Alachkar H, Mutonga M, Malnassy G, Park JH, Fulton N, Woods A, Meng L, Kline J, Raca G, Odenike O, Takamatsu N, Miyamoto T, Matsuo Y, Stock W, Nakamura Y, Oncotarget, 1/1/2015
• Telomerase Imetestat for patients with essential thrombocythemia  
  Baerlocher G., Leibundgut E, Ottmann OG, Spitzer G, Odenike O, McDevitt MA, Roth A, ,Daskalakis M, Burington B, Stuart M, Snyder DS, N Engl J Med, 1/1/2015

Books/Book Chapters

• Treatment strategies-Hematology 
  Chapter: Targeted therapeutic approaches for myelofibrosis 
  Curran E and Odenike O2014
• Oncology – An Evidence-Based Approach 
  Chapter: Acute Lymphoblastic Leukemia 
  Page 1173 - 2000Odenike OM, Michaelis L, Stock WEditors: Chang AE, Ganz PA, Hayes DF, Kinsella T, Pass HI, Schiller JH, Stone R, Stretcher.Edition 1st,2006
• Griffith’s 5-minute Clinical Consult 
  Chapter: Myeloproliferative diseases 
  Page 736 - 737Odenike OMEditors: Mark R. Dambro.Edition 13th,2005

Abstracts/Posters

• Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ...
  Olatoyosi Odenike, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodyspl...
  Olatoyosi Odenike, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS
  Olatoyosi Odenike, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

• Results from the first-in-human study of mivebresib (ABBV-075), a pan-inhibitor of bromodomain and extra terminal proteins, in patients with relapsed/refractory acute ... 
  2019 ASCO Annual Meeting - 6/1/2019
• A Multi-Institution Comparison of Mitoxantrone, Etoposide and Cytarabine (MEC) Vs High-Dose Cytarabine and Mitoxantrone (Ara-C Couplets) Therapy for Patients with Rela... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Clonal Hematopoiesis and how it can confound the results of germline and somatic mutation testing 
  1/1/2016

Other

• ”Ibrutinib will change the CLL landscape” Expert opinion on CLL Resonate Ibrutinib study 
  Oncology times
  1/1/2014
• It takes more than a JAK-hammer to crack the case 
  ASH News Daily
  1/1/2013
• Nature Reviews Drug Discovery 10: 717-18, Companies hope for kinase inhibitor JAKpot 
  News and Analysis
  1/1/2011